1st Cardiology Department, 'Hippokration' General Hospital, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Radcliffe Department of Medicine, Division of Cardiovascular Medicine, University of Oxford, Oxford OX3 9DU, UK.
Int J Mol Sci. 2021 Jun 21;22(12):6607. doi: 10.3390/ijms22126607.
Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been associated with excess mortality worldwide. The cardiovascular system is the second most common target of SARS-CoV-2, which leads to severe complications, including acute myocardial injury, myocarditis, arrhythmias, and venous thromboembolism, as well as other major thrombotic events because of direct endothelial injury and an excessive systemic inflammatory response. This review focuses on the similarities and the differences of inflammatory pathways involved in COVID-19 and atherosclerosis. Anti-inflammatory agents and immunomodulators have recently been assessed, which may constitute rational treatments for the reduction of cardiovascular events in both COVID-19 and atherosclerotic heart disease.
由严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）引起的 2019 年冠状病毒病（COVID-19）在全球范围内与超额死亡率相关。心血管系统是 SARS-CoV-2 的第二大常见靶标，可导致严重并发症，包括急性心肌损伤、心肌炎、心律失常和静脉血栓栓塞，以及其他主要血栓事件，这是由于直接内皮损伤和过度全身炎症反应所致。本综述重点关注 COVID-19 和动脉粥样硬化中涉及的炎症途径的相似性和差异性。最近评估了抗炎药和免疫调节剂，它们可能构成降低 COVID-19 和动脉粥样硬化性心脏病中心血管事件的合理治疗方法。
